Related Experiment Video
Updated: Sep 28, 2025

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers
Juliet E Wolford1, Erin Ferrigni1, Daniel Margul1
1Division of Gynecologic Oncology, University of Cincinnati, Cincinnati, OH, USA.
Purpose Of Review:
The treatment of patients with advanced gynecologic malignancies remains challenging. Advancements in genomics have led to recognition and development of individualized therapeutic targets. This article reviews the current trends in precision medicine for treatment of gynecologic cancers.
Recent Findings:
With the identification of the molecular aberrations inherent to gynecologic malignancies, we have discovered targetable mutations. Specific to ovarian, endometrial and cervical cancers, potential therapeutic targets that have been identified and shown to have benefit include: hormonal therapies, anti-angiogenic agents, poly-ADP-ribose polymerase inhibitors (PARPi), and immunotherapy. The adoption of targeted therapeutics for the treatment of gynecologic cancers has been gradual, but we have started to see the rapid employment of novel targeted agents into clinical trial development, leading to new treatment approvals. However, there are challenges to the universal precision medicine implementation, and future studies need to identify, discover, and validate robust biomarkers with strong prognostic/predictive capabilities.
Insights
Precision medicine offers targeted therapies for advanced gynecologic cancers like ovarian, endometrial, and cervical cancers. Identifying robust biomarkers is crucial for future treatment advancements and approvals.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Advanced gynecologic malignancies present significant treatment challenges.
- Genomic advancements are driving the development of individualized therapeutic strategies.
Purpose of the Study:
- To review current trends in precision medicine for gynecologic cancer treatment.
- To highlight the role of molecular aberrations in identifying targetable mutations.
Main Methods:
- Review of current literature on precision medicine in gynecologic oncology.
- Identification of molecular targets and therapeutic agents.
Main Results:
- Targetable mutations in ovarian, endometrial, and cervical cancers include hormonal therapies, anti-angiogenic agents, poly-ADP-ribose polymerase inhibitors (PARPi), and immunotherapy.
- Novel targeted agents are rapidly entering clinical trials, leading to new approvals.
- Challenges remain in universal precision medicine implementation.
Conclusions:
- Precision medicine, utilizing targeted therapies, is transforming gynecologic cancer treatment.
- Further research is needed to identify and validate predictive biomarkers for optimal patient selection.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
07:03Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
Published on: December 1, 2023
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...